MoonLake Immunotherapeutics
MLTX· Nasdaq
Released May 11, 2026, before the open
10-Q filed May 11, 2026, 41 days after period end · 0001821586-26-000007
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | -$69.71M | -$39.94M | -$13.67M | -$9.00M |
| EPS Diluted | -$0.98 | -$0.63 | -$0.22 | -$0.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
MoonLake Immunotherapeutics · CIK 1821586 · Engraved from SEC EDGAR